EXCLUSIVE ONLINE CONTENT
DURECT Corporation recently announced that further development of a long-acting injectable HIV investigational product utilizing DURECT’s SABER technology has triggered a $10-million milestone payment from Gilead Sciences, Inc. to…….
Kaleido Biosciences, Inc. recently announced plans to develop Microbiome Metabolic Therapies (MMT) to enhance the effects of cancer immunotherapies under a new…….
Nkarta Therapeutics Raises $114 Million in Series B Financing to Advance Multiple Programs Into Clinical Trials
This financing is intended to support two clinical trial programs of NKX101, Nkarta’s allogenic NK cell therapy targeting NKG2D, in patients with either…..
Cara Therapeutics, Inc. recently announced it has entered into a non-exclusive commercial license agreement with Enteris BioPharma, Inc. for oral formulation rights to…..
Viral vectors, such as adeno-associated virus (AAV), are expected to play a pivotal role in gene therapies for neurology indications, as this vector type has been found to be the most…..